Inhaled statins as bronchodilators to improve lung function in respiratory diseases

A technology of statins and inhalers, which is used in the field of inhaling statins as bronchodilators to improve lung function in respiratory diseases, and can solve problems such as lung function decline and airway stenosis

Pending Publication Date: 2021-12-03
RGT UNIV OF CALIFORNIA +1
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, excessive smooth muscle bronchoconstriction remains a daily problem for patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhaled statins as bronchodilators to improve lung function in respiratory diseases
  • Inhaled statins as bronchodilators to improve lung function in respiratory diseases
  • Inhaled statins as bronchodilators to improve lung function in respiratory diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0184] Example 1: Relaxation of ASM Contractility

[0185] The following experiments demonstrate that statins induce relaxation of the ASM in resting, non-stimulated cells.

[0186] Contractile Force Screening : Human ASM cells in 96-well plates in custom NuSil TM Grow to confluence on 8100 Elastic Substrate (Avantor, Inc., Radnor, PA) (R. Rokhzan et al., LabInvest (2019) Vol. 99 No. 1: No. 138 -145 pages). Fluorescent beads (approximately 400 nm in diameter) were embedded in the substrate surface so that traction forces could be calculated based on the displacement of these beads. To measure traction force, an inverted epifluorescence microscope (DMI6000B, Leica Inc., Germany) equipped with a heated chamber (37°C), a monochrome camera (Leica DFC365 FX) and a motorized stage was used. Aerial images of substrate-embedded fluorescent beads were recorded at 10X magnification. Based on the displacement of the bead relative to the cell-free model (resolution about 15 μm), ...

Embodiment 2

[0197] Example 2: histamine-induced contraction

[0198] These experiments were performed to determine the ability of statins to reduce ASM contraction induced by exposure to histamine.

[0199]Cells were pretreated with pitavastatin and simvastatin acid at doses of 0 μM, 0.08 μM, 0.4 μM, 2 μM, 10 μM or 50 μM for 24 hours and then stimulated with histamine (10 μM). pitavastatin ( Figure 4A ) and simvastatin ( Figure 4B ) significantly reduced histamine-induced ASM contractions in both complete and serum-free media ( Figure 4C ). In complete medium, 0.08 μM pitavastatin was sufficient to inhibit histamine-mediated contraction of ASM ( Figure 4A ). However, to achieve similar protection, a 5× molar excess of simvastatin (SA) ( Figure 4B ). In serum-free medium, 0.4 μM pitavastatin and 10 μM simvastatin provided a similar degree of protection against histamine-induced contractions.

[0200] The time-dependent effects of SA and pitavastatin suggest that the ASM rela...

Embodiment 3

[0204] Example 3: deep breathing relaxation

[0205] This experiment shows that pitavastatin enhances the ASM relaxation effect of simulated deep breathing compared to the beta2-agonist isoproterenol.

[0206] Normal ASMs were treated with pitavastatin (1 μM, 24 hours, n=7), isoproterenol (10 μM, 30 minutes, n=6) or vehicle (n=7) and detected by CFS as described above. Figure 12 A shows that pretreatment with pitavastatin significantly inhibited basal ASM contraction compared to untreated controls. Shrinkage values ​​normalized to untreated controls are shown. Figure 12 B shows that ASM cells rapidly and significantly abolished their contractions in response to a subsequent single stretch-no-stretch maneuver simulating deep breathing (10% amplitude, 4 sec duration). The contractile force is gradually recovered within 180 seconds. While force ablation was similar in all three groups, subsequent force recovery was significantly inhibited by pitavastatin treatment (*p<0.05...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure relates to methods for relaxing airway smooth muscle tissue, alleviating or preventing bronchospasm, and treating lung diseases by administering an HMG-CoA reductase inhibitor (statin) directly to lung tissue by inhalation. The disclosure also relates to formulations and compositions useful for the practice of methods of the disclosure.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS [0002] This international application claims the benefit of U.S. Provisional Application 62 / 826,620, filed March 29, 2019, and U.S. Provisional Application 62 / 906,427, filed September 26, 2019, pursuant to 35 U.S.C. § 119(e); these The contents of each provisional application in the provisional application are incorporated herein by reference in their entirety. [0003] Statement Regarding Rights to Inventions Made Under Federally Funded Research and Development [0004] This invention was made with government support under Grant No. NIH / NHLBI K08 HL114882-01A1 and a California Regional Primate Research Center Pilot Grant (P51 OD011107). The US Government has certain rights in this invention. Background technique [0005] Nearly 20 million people in the United States and more than 339 million people worldwide are affected by asthma, who experience wheezing and shortness of breath due to excessively narrowed airways. See, eg, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/12A61K31/405A61K31/40A61K31/505A61K31/22A61K31/47
CPCA61P11/08A61K45/06A61K9/0075A61K9/008A61K9/0078A61K31/366A61K31/40A61K31/4418A61K31/404A61K31/47A61K31/22A61K31/505A61K31/573A61K2300/00A61K31/137A61K31/24A61K31/381A61K31/4025A61K31/439A61K31/44A61K31/4545A61K31/46A61K31/4741A61K31/522A61K31/5386A61K39/3955A61K39/39566
Inventor A·A·扎基C·C·戈什R·克里希南
Owner RGT UNIV OF CALIFORNIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap